Dr. Daniel R. Greenwald, M.D.
Medical Oncology (Medical Oncology Physician)
309 W Quinto St
Santa Barbara, CA 93105
Who else practices at this address →
Santa Barbara County includes primary care (2% of residents) and mental health (21% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- Stanford University School of Medicine (2000)
- Years since graduation
- 26
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 881
Licensed in California since 2001, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2000Medical school: Stanford University School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
CA license A75508 (first issued 2001; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Ronald Reagan UCLA Medical Center Los Angeles, CA
- Santa Barbara Cottage Hospital Santa Barbara, CA
- Goleta Valley Cottage Hospital Santa Barbara, CA
- Santa Ynez Valley Cottage Hospital Solvang, CA
Medical groups
- The Regents of the University of California (1,462 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 881
- Services billed
- 244,884
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Injection, pembrolizumab, 1 mg | 36,800 | 22 |
| Injection, daratumumab, 10 mg and hyaluronidase-fihj | 32,220 | 19 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 18,700 | 15 |
| Injection, denosumab, 1 mg | 10,380 | 39 |
| Injection, fosaprepitant, 1 mg | 6,150 | 13 |
| Injection, palonosetron hcl, 25 mcg | 1,430 | 28 |
| Established patient office or other outpatient visit, 30-39 minutes | 1,426 | 611 |
| Injection, dexamethasone sodium phosphate, 1 mg | 1,376 | 38 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 791 | 272 |
| Infusion, normal saline solution, 250 cc | 677 | 104 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisone Other prescribers in Santa Barbara, CA | 61 |
| Abiraterone Acetate | 34 |
| Tamoxifen Citrate Other prescribers in Santa Barbara, CA | 30 |
| Dexamethasone Other prescribers in Santa Barbara, CA | 27 |
| Gabapentin Other prescribers in Santa Barbara, CA | 23 |
| Anastrozole Other prescribers in Santa Barbara, CA | 15 |
| Venclexta (venetoclax) | 14 |
| Eliquis (apixaban) Other prescribers in Santa Barbara, CA | 13 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 6 companies reported 6 payments worth $323 in total to this clinician.
| Beone Medicines USA, Inc. | $133 |
|---|---|
| E.r. Squibb & Sons, L.l.c. | $91.85 |
| Acrotech Biopharma Inc. | $34.83 |
| Alnylam Pharmaceuticals Inc. | $33.22 |
| Lilly USA, LLC | $18.40 |
| Gilead Sciences, Inc. | $12.42 |
| Food and Beverage | $311 |
|---|---|
| Education | $12.42 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Gilead Sciences, Inc. Nov 24, 2025 | Education Trodelvy · ONC · in-kind Company’s description;4219165;G360;10062044 | $12.42 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $200 in research payments for these studies, mostly to the institutions running them.
- Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma
AbbVie Inc. · Completed · NCT02947347
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.